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Background: Gaucher disease, an autosomal recessive condition due to deficiency of lysosomal
glucocerebrosidase, is a multisystemic disease, with variable age of onset, severity and progression. It is classified
into subtypes delineated by the absence (type 1) or presence (type 2 and 3) of primary nervous system
involvement.
The ethnically diverse, largely immigrant population in South Florida has a spectrum of Gaucher disease
phenotypes, creating a challenge for optimization of disease management and an opportunity to explore treatment
patterns.
Methods: Ninety-three records from patients with Gaucher type I in South Florida were retrieved from the
International Collaborative Gaucher Group (ICGG) Registry. Individual genotypes were correlated with severity scores
and success at achieving published therapeutic goals for haemoglobin concentration, platelet count, spleen
volume, liver volume and amelioration of bone pain and bone crises.
Results: The majority of patients were diagnosed during the fifth decade of life. Almost two-thirds were
homozygous for the N370S mutation, reflecting the large Ashkenazi Jewish population in South Florida. The
majority received imiglucerase (62.8%) at various intervals. 24.5% of patients underwent splenectomy before starting
enzyme replacement therapy. After a median 12 treatment years, South Florida patients matched or exceeded the
ICCG 4 year therapeutic goal achievement for platelet count (85.4% vs. 79.6% success), spleen volume (93.3% vs.
78.0% success), liver volume (93.4% vs. 90.6% success), and bone crises (100% vs. 99% success). Nevertheless, fewer
patients with intact spleens had sustained achievement of all 6 therapeutic goals (30.4% versus 41.4%) and only
40% of the splenectomy patients sustained achievement of 5/5 possible goals. 54.7% of the intact spleen patients
continued to have bone pain vs. 29.8% in ICCG. Significantly, only 37% of the ICGG patient cohort had bone pain
prior to initiation of treatment compared to 73.4% of the South Florida patients (moderate or severe pain in 59.6%).
Conclusions: Demographic characteristics are a significant determinant of the differences in response to treatment
observed in South Florida Gaucher patients compared to those described in the international population enrolled
in the ICGG Gaucher Registry. Individual genotypes and ethnic background are important considerations for
optimizing patient care for Gaucher disease.
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Gaucher disease (GD) is an autosomal recessive lyso-
somal storage disorder that, with the exception of rare
patients with saposin C deficiency, is caused by muta-
tions in the glucocerebrosidase gene, GBA1 [1]. Deficient
glucocerebrosidase activity leads to accumulation of the
enzyme’s substrate, glucocerebroside (glucosylceramide),
in tissue macrophages primarily in the liver, spleen and
bone marrow. Subject to genotype, other genetic modi-
fiers [2,3] and undefined genetic, epigenetic and environ-
mental factors, untreated patients with GD may be
asymptomatic with few signs of disease or present with
combinations of hematologic abnormalities, hepatosple-
nomegaly, skeletal disease, growth retardation, and de-
creased health-related quality of life [1]. GD type 1
(GD1), found in approximately 90% of known GD pa-
tients worldwide, is differentiated from GD type 2 and
GD type 3 by the absence of overt, early onset neuro-
logical signs and symptoms. However, distinct late onset
neurological symptoms such as peripheral neuropathy
and Parkinson disease may occur in GD1 [4].
The incidence of GD1is estimated at 1/50,000-75,000
live births in non-Jewish populations in North America,
Europe and Australia [5,6]. Of more than 350 GBA1
variant alleles that are associated with GD, 6 mutations
account for 98% of those found in the Ashkenazi Jewish
population in which GD1 is especially prevalent [7]. One
in 10–15 Ashkenazi Jews is a carrier for a GBA1 muta-
tion projecting a disease incidence of 1/600 live births
[8]. However, the observed disease prevalence among
North American Ashkenazi Jews is substantially lower
than predicted. In South Florida, home to an estimated
500,000 Ashkenazi Jews [9], only approximately 100
Ashkenazi Jews with GD1 have been identified over a
20 year period (NJW, personal observation). This lower
than expected prevalence is comparable to other US
metropolitan areas with large Ashkenazi Jewish popula-
tions [10,11]. The difference between observed and pre-
dicted cases with GD1 may be readily explained by the
highly variable penetrance resulting in large numbers of
asymptomatic individuals who never come to medical at-
tention although missed diagnoses cannot be excluded
[12]. Among western non-Jewish populations, the preva-
lence of GD1 is also less than predicted: 1/150,000-
300,000 in French and Spanish national registries
[13,14]. It is unclear to what extent phenotypic hetero-
geneity contributes to this finding in light of evidence
that the GD1 clinical phenotype tends to be more severe
in non-Jewish patients compared to Ashkenazi Jews [15].
Here, we present a demographic and genotypic profile
for 93 GD1 patients who live in South Florida and are
enrolled in the ICGG Gaucher Registry and correlate
genotype with validated severity scores and hematologic,
visceral and skeletal therapeutic outcomes.Methods
Patient population
The ICGG Gaucher Registry was launched in 1991 to
track the clinical, demographic, genetic, biochemical and
therapeutic characteristics of patients with GD through-
out the world, irrespective of disease severity, treatment
status or treatment choice [16]. Governance and scien-
tific direction is provided by an international group of
physician experts in GD, with operational support from
Genzyme, a Sanofi company (Cambridge, Massachusetts).
For this report, we independently analyzed the medical
records of all patients with Type 1 GD at the University
Research Foundation for Lysosomal Storage Diseases
South Florida site who enrolled patients into the ICGG
Gaucher Registry from 1991-June 2011. All participating
patients gave informed consent to participate in the ICCG
Registry using forms approved at the time of their enroll-
ment by the Western Institutional Review Board.
Genotype
Genotype was obtained for most patients by PCR spe-
cific oligonucleotide screening for 5 common mutations
prevalent in the Ashkenazi Jewish population (N370S,
L444P, 84GG, IVS2 + 1, R496H; Genzyme Genetics, ac-
quired by Laboratory Corporation of America in May
2010). Samples from some patients with unidentified al-
leles were referred to the ICGG Registry Genotyping
Service at the laboratory of H. Ronald Scott, MD, PhD
at the University of Washington, Seattle, WA, USA for
whole gene sequencing.
Gaucher disease severity scoring
Patients were categorized based on a validated DS3 dis-
ease severity scoring system [17], performed according
to instructions in Figure 1 and evaluated per instructions
in Table 1. For treated patients, baseline DS3 scores
were calculated just prior to or at the time of initiation
of enzyme replacement therapy (ERT). For patients
never treated with ERT, the DS3 score was calculated at
the most recent follow up point for which complete data
was available.
Therapeutic goals
In 2008, an ICGG Registry benchmark analysis evaluated
the attainment of six previously suggested therapeutic
goals (for hemoglobin concentration, platelet count,
spleen volume, liver volume, bone pain, and bone crisis)
in 195 non-splenectomized patients with type I GD after
4 years of imiglucerase treatment [18]. Here, we present
therapeutic outcomes relative to the same therapeutic
goals for our cohort of patients treated with enzyme re-
placement therapy for a minimum of 3 years. Results are
reported for the date of latest follow up and separately
for patients with a history of pre-treatment splenectomy.
Figure 1 GD-DS3.
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Demographic analyses used standard descriptive statis-
tics (frequencies and percentages). DS3 scores are sum-
marized using means and standard deviations. ANOVA
testing was performed using a 2 tailed T test (Excel,
Microsoft Corporation).Results
Demographics and genotype
93 individuals (mean age 62.1 years; range 25–91) were
initially eligible. 57 (61.2%) were women. The mean (SD)
age at first assessment was 49.9 years (SD 19, range: 4.2
to 83.6y). 75 patients (80.6%) reported Ashkenazi Jewish
ethnicity. Five lacked genotype information. There were
4 sibling pairs. Of 84 unrelated patients with genotype
data, 52 (61.9%) were homozygous for the N370S allele
and 29 (34.5%) carried one N370S allele (Table 2).
Among patients of Ashkenazi Jewish ethnicity, 51 of 71
with known genotypes were N370S homozygous (71.8%)
while only 2 of 17 non-Jewish patients (11.8%) were
homozygous for N370S.For the 88 patients with known genotypes, sufficient
information to calculate baseline DS3 scores was avail-
able for 81 patients. DS3 scores in N370S homozygous
patients (N = 48) were highly variable but generally in
the mild to moderate range (Table 3). Because of small
numbers of patients in each sub-group, the only geno-
type with a statistically significant difference in DS3
score from N370S/N370S was N370S/L444P (N = 10) in
which severity was generally severe. Severity was also
significantly higher when N370S/84GG patients (N = 4)
are grouped with the N370S/L444P patients. The broad
range of genotypes and disease severity in South Florida
patients is shown is shown in Figure 2 which emphasizes
the highly variable severity scores in N370S homozygous
patients with approximately half the patients falling
within the moderate to marked severity range.
Treatment status (93 patients)
Fifteen patients have not received disease-specific treat-
ment primarily because comprehensive initial and serial
assessments (NJW) indicated a clinically mild phenotype.
ERT access was not problematical. One patient with
Table 1 Gaucher disease type 1 DS3 scoring
General
instructions
1. Record date of assessment
2. For each assessment, determine the GD1 DS3 score of the patient at the time of evaluation
(See notes below regarding specific assessments).
a. If current data are not available for all assessments when the DS3 score is calculated, data from
previous evaluations may be used if the patient’s overall clinical status has remained stable and
assessments were collected within the following period of time prior to the current date:
• Bone imaging 12–24 months
• Hematological 12–24 months
• Visceral imaging 12–24 months
b. If bone marrow infiltration and/or bone mineral density data are not available at the time of assessment or from
previous evaluations, the GD1 has been optimized to be accurate and consistent without these parameters.
c. All other assessment scores within the time frames described above are required.
DS3 score calculation
1. First calculate the average Disease Domain Scores by adding the assessment scores for
each domain (bone, haematological, visceral) and dividing by the number of assessment scores
completed. Do not include assessments that were marked “not available” (NA)
2. The total GD1 DS3 score is the sum of the three Disease Domain Scores.
Maximum possible
DS3 score
1. The maximum possible DS3 score is 19.
2. In initial validation testing using 20 patient cases scored at 2 different time points, no patient received a score
higher than 13 and scores above 9 correlated with an expert assessment of “severe disease”.
Interpretation of GD1
DS3 scores
1. 0-3 Borderline to mild disease
2. 3–6 Moderate disease
3. 6–9 Marked disease
4. >9 Severe disease
Notes regarding
specific assessments
1. Lytic lesions, AVN or pathologic fracture “present” means any new occurrence in the past 12 months.
2. Bone marrow infiltration may be reported either semi-quantitatively (BMB score) or qualitatively (mild, moderate, marked to
severe.
3. For bleeding, an assessment of moderate (no transfusions) or severe (transfusion needed) should be based on
bleeding considered by the assessor to be related to GD, whether due to low platelet count, other hemostatic
disorders or vascular disease such as portal hypertension.
4. Assessment of bone pain should be based on severity in the absence of analgesics and should consider only pain
resulting from GD rather than pain attributable to other concurrent musculoskeletal diseases.
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the imiglucerase shortage/interruption beginning in June
2009, virtually all patients who required treatment re-
ceived imiglucerase. Two patients of unknown genotype
who died prior to 1995 received alglucerase 60 U/kg
every 2 weeks. They are excluded from the genotype and
response analyses . At last evaluation through June 2011,
49 patients were receiving imiglucerase of whom 1 was
infused weekly, 33 every two weeks, 2 every three weeks
and 13 every four weeks (Table 4). Doses ranged from
20–120 U/kg but most received 30–60 U/kg. Tenpatients received velaglucerase alfa mostly every 2 weeks
at 60 U/kg. Four patients were treated with oral miglu-
stat 100 mg three times daily. 13 patients had treatment
interruptions– 3 for infusion reactions prior to 2009 and
10 due to the imiglucerase shortage. One has been stable
since splenectomy in 1997 and the other 12 are clinically
stable.
Treatment outcomes and attainment of therapeutic goals
Of the initial 93 patients, 61 are included in this analysis.
Fifteen untreated patients, 12 patients treated for less


















*Includes 1 sibling pair.
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excluded. The median treatment duration at the time of
analysis is 12 years (Range: 3-19y; Mid-quartile range:
6.6-16.5y). Fifteen patients (24.5%) had splenectomy
prior to treatment initiation.
17 patients are deceased of whom 4 had undergone
splenectomy. The mean age (SD) at death was 71.9
(15.4) years; median age at death (range): 71.5 years
(28y-92y); interquartile range: 64.5y-83.8y. The geno-
types of deceased patients were 13 - N370S/N370S, 2
N370S/L444P and 1 N370S/V394L. The causes of death
are shown in Table 5. The mean pre-treatment DS3
score for the 13 N370S homozygous deceased patients is
5.50 (SD 1.79) compared to 3.22 (SD 2.05) for the
treated N370S homozygous patients who remain alive
(p = 0.002). The mean age (SD) at which ERT was initi-
ated was 66.0 (SD 10.6) years for the deceased N370S
homozygous patients and 52.1 (SD 14.4) years for the
still surviving N370S homozygous patients (p = 0.006).Table 3 South Florida GD1 patients: Mean DS3 scores per gen
Genotype M
N370S/N370S (N = 48)
N370S/84 GG compound heterozygote (N = 4)
N370S/L444P (N = 10)
N370S/unidentified (N = 5)
N370S/V394L (N = 5)
N370S/L444P or 84GG compound heterozygotes and (N = 14)
N370S/Y212H (N = 2 sisters)
N370S/IVS2 + 1 (N = 2)
N370S/F216Y (N = 1)
N370S/RecNCI1 (N = 1)
N370S/Y135X (N = 1)
R463C/K198 (N = 1)
L444P/unidentified (N = 1)
Statistical comparison is for the N370S/N370S genotype versus the other genotypesAs shown in Table 6, 26 concurrent malignancies de-
veloped in 24 of 93 patients (25.8%). Two patients had 2
cancers (cutaneous melanoma and localized breast CA;
cutaneous squamous cell CA and cervical CA in situ).
Four patients have a significant monoclonal gammopathy
but none has yet developed overt multiple myeloma.
Cancers were diagnosed at a median age of 67 years
(47–83 y). Of the 24 patients with concurrent malignancies,
5 have never been treated definitively for GD1 (Table 4).
After a median 12 treatment years, South Florida pa-
tients matched or exceeded the ICCG 4 year therapeutic
goal achievement for platelet count (85.4% vs. 79.6% suc-
cess), spleen volume (93.3% vs. 78.0% success), liver vol-
ume (93.4% vs. 90.6% success), and bone crises (100% vs.
99% success). Nevertheless, fewer patients with intact
spleens had sustained achievement of all 6 therapeutic
goals (30.4% versus 41.4%) and only 40% of the splenec-
tomy patients sustained achievement of 5/5 possible
goals (Table 7). Of 6 South Florida patients who “failed”
therapeutic goal criteria for hemoglobin concentration, 5
had concurrent hematological diagnoses: auto-immune
hemolytic anemia [1], acute myelocytic leukemia [1],
myelodysplasia [1], chronic kidney disease [2].
54.7% of the intact spleen patients (and 53.3% of the
splenectomy patients, for whom there is no comparison
group) continued to have bone pain vs. 29.8% in ICCG.
On average, there was no age difference between pa-
tients with residual bone pain and those free of pain. Of
note, only 37% of the ICGG patient cohort had bone
pain prior to initiation of treatment compared to 73.4%
of the South Florida patients (moderate or severe pain in
59.6%). Of 28 patients with baseline bone pain scaled as
moderate or worse, 20 (71.4%) failed to realize the thera-
peutic goal for bone pain at their most recent evaluation.otype category
ean DS3 score (SD) 95% CI P value (T test)
3.86 (2.31) 3.21-4.51 Reference
6.98 (1.85) 5.17-8.79 NS
6.82 (1.08) 6.15-7.49 0.018
4.30 (2.20) 2.37-6.23 NS
4.80 (2.29) 2.79-6.81 NS
















Figure 2 DS3 scores (Y axis) per GBA genotypes in 89 South
Florida patients with GD1.
Table 5 Causes of death in 17 deceased South Florida
treated GD1 patients
Cause of death Total
number of pts
Number of pts with
splenectomy
Parkinsonism* 3 2




Dementia without Parkinsonism 2
Non-Hodgkin’s lymphoma 1 1
Lung cancer, metastatic 1
Cerebrovascular accident 1





with illicit IV drug use
1
*Age at Parkinson disease diagnosis: 45, 54, and 63 years respectively.
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or pain no worse than mild, 15 (42.8%) had bone pain at
their most recent evaluation. Age at inception of ERT
was not significantly associated either with severity of pre-
treatment bone pain or with therapeutic goal “failure” due
to persistent bone pain. However, of the 61 patients in-
cluded in the therapeutic goal analysis, only 9 patients
were younger than 30 years of age when ERT was begun
and only 4 were younger than 18 years. Regardless of age
at inception of treatment, severity of pre-treatment bone
pain was a key predictor for persistent bone pain. Age at
commencement of ERT also did not appear to be a
significant determinant of failure to achieve therapeutic
goals other than bone pain. Among our patients, poor
compliance with treatment schedules was not a contribu-
tory factor to poor therapeutic responses.Table 4 Treatment Status of 91 South Florida GD1 patients
as of the most recent evaluation through June 2011*
No. of pts ERT dose (Units/kg)




Q2W 3 14 16
Q3W 2
Q4W 1 9 3




Miglustat 100 mg po TID 4
Treatment interrupted
and not resumed (total)
13
Severe infusion reactions 3
Treatment shortage 10
*Two patients with unknown genotypes who were treated solely with
alglucerase prior to 1994 are excluded from this analysis.The initial total DS3 bone domain score, although in-
cluding heavily weighted information about avascular
necrosis, lytic lesions, fractures, bone marrow infiltration
and bone density, was less likely to predict pain out-
comes than the bone pain score itself. There also was no
significant association between the baseline DS3 bone
domain score and composite attainment of therapeutic
goals in either patients with intact spleens or in those
with splenectomy (Table 8). Likewise, neither the total
pre-treatment DS3 score nor the GBA genotype was
predictive of outcome in terms of achievement of the 6
therapeutic goals that were examined.
Discussion
To our best estimate, the 93 patients included in this re-
port constitute at least 75% of known GD1 patients liv-
ing in South Florida during a 22 year period. During that
time, a 1990 population of 3.5 million in which 57%
were non-Hispanic White has grown to 5.5 million with
only 41% being non-Hispanic White [19]. There are ap-
proximately 2.3 million Hispanic or Latino South Flori-
dians of any race and 1.1 million of Black-American
ethnicity. 37% of the region’s population is foreign-born
and 32% were born elsewhere in the United States.
Nevertheless, our patients with GD1 continue to be
genotypically and phenotypically different from patient
populations that have been reported from various
European and Latin American countries and much
closer in characteristics to other patients with GD1
living primarily in the northeastern United States,
California and in Israel (Table 9).
Compared to the GD1 patients from the Northeast
United States described by Taddei et al. [11], somewhat
fewer South Florida patients were Ashkenazi Jews, were








Monoclonal gammopathy 4 54, 68, 70#, 82# 68.5
Cutaneous Squamous CA 5 59, 66, 66, 77, 80 69.6
Myelodysplasia, AML 3 51*, 63*, 72* 62.0
Non-Hodgkin’s lymphoma 3 59, 74*, 83 72.0
Breast carcinoma 3 47#, 72#, 75 64.7
Cutaneous Melanoma 2 57, 71 64.0
Prostate carcinoma 2 65, 75 70.0
Bladder carcinoma 1 80 80.0
Lung cancer 1 62* 62.0
Fallopian tube carcinoma 1 49§# 49.0
Cervical carcinoma in situ 1 53 53.0
*Cause of death.
§BRCA2 mutation.
#Never treated with ERT or SSIT.
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Our patients were significantly older when initially
assessed (mean age 49.9 years (SD 19.0) versus 39.2 years
(SD 18.8), p < 0.0001). The difference in age and
increased years at risk may explain why the occurrence
of malignancy was greater in our patient group (24/93
(25.8%) versus 46/367 (12.0%)). Among our patients with
cancers, hematological malignancies were the most
prevalent. However, despite strong evidence for a sub-
stantial increased risk for this malignancy in older
patients with GD1 [20-23], none of our patients have yet
developed myeloma although four have monoclonal
gammopathy of uncertain significance. Our experience
does not suggest that patients with GD1 have a greater
risk for developing the most common solid tumorsTable 7 Attainment of therapeutic goals: South Florida patien
Therapeutic goal South Florida GD1
(Median treatment:12 years mini
Bone pain (N = 61) 45.3%#
Hemoglobin (N = 61) 90.6%*
§Platelets (N = 46) 85.4%
§Spleen volume (N = 46) 93.3%
Liver volume (N = 61) 93.4%
Bone crises (N = 61) 100%
§Attained 6/6 goals (N = 46) 30.4%
§§Attained 5/5 goals (N = 15) 40.0%
§Intact spleen patients only.
§§Splenectomy patients.
#63% of the ICGG patient cohort had no reported bone pain prior to initiation of tr
initiation of treatment; bone pain was scaled as moderate or worse in 59.6%.
*In 5/6 patients, Hb was depressed because of concurrent illnesses at evaluation po
chronic kidney disease [2]).(lung, breast, prostate, colorectal, pancreatic) than un-
affected individuals in the general population.
With the exception of N370S/N370S, the number of
our patients in each GBA1 genotype sub-set is small.
Nevertheless, the DS3 scores are consistent with the
consensus perception of “severity” of GD1 genotypes
and our results complement the validity testing of the
DS3 instrument [17]. In most western non-Jewish popu-
lations, 20-30% of patients with GD1 are N370S/L444P
and moderately to severely affected prior to starting
treatment. The mean DS3 score for our N370S/L444P
patients (6.82) is consistent with this experience. No
N370S/L444P patient in our study had a pre-treatment
DS3 score in the mild range. There was more DS3 score
heterogeneity among other N370S heteroallele genotypes
including N370S/V394L (generally associated with mild
phenotypes) [24] and N370S/IVS2+1 (generally associated
with clinically more severe disease [25].
As expected, there was substantial variability in the se-
verity scores among N370S homozygous patients [26].
Although the lowest DS3 scores (<2.00) were confined
to the N370S/N370S patients, half of the N370S homo-
zygous patients had DS3 scores that were in the moder-
ate range or higher. Skeletal disease, as measured with
the Hermann score and Zimran Severity Score Index (SSI)
is reported to worsen with age in untreated, non-
splenectomized homozygous GD1 patients [11]. However,
in similar patients, we did not find a significant correlation
between patient age at first assessment and either bone
domain DS3 score (ρ = 0.21) or total DS3 score (ρ = 0.25).
As regards treatment response, pending completion of
a larger, multicenter study designed to examine serial
changes in DS3 scores in both treated and untreated
patients (Clinicaltrials.gov; NCT01136304), we elected to
evaluate our patients in terms of achievement of thera-
peutic goals for hemoglobin concentration, plateletts with GD1 and the ICCG benchmark cohort [18]
patients
mum treatment: 3 years)
ICGG cohort (N-195)









eatment. 73.4% of the South Florida patients reported bone pain prior to
int (auto-immune hemolytic anemia, acute myeloid leukemia, myelodysplasia,
Table 8 Lack of association between the baseline DS3 bone domain score and composite attainment of therapeutic
goals
Therapeutic goals attained Number of patients Mean DS3 score (SD) 95% Confidence interval ANOVA P value
Intact spleen pts (N = 45) 0.508
6 of 6 14 2.70 (1.60) 1.86–3.54
5 of 6 21 3.01 (1.71) 2.28–3.74
4 of 6 10 2.23 (1.97) 1.01–4.20
Splenectomy pts (N = 15) 0.282
5 of 5 6 4.26 (2.33) 2.40–6.12
4 of 5 5 5.82 (1.03) 4.92–6.72
3 of 5 3 6.08 (1.28) 4.63–7.53
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crises. These short term goals are not necessarily disease
specific over an extended period of observation and they
are an incomplete representation of all the elements that
are integral to capturing the essence of clinical response
to treatment for life long chronic illnesses such as GD1.
Nevertheless, regulatory approvals of new therapy for
GD1 and most reports of 4–10 year treatment outcomes
have relied heavily, and sometimes exclusively on these
six parameters [18,27], and sustained cumulative main-
tenance of these specific therapeutic goals has been pro-
posed as a benchmark for therapeutic efficacy and as a
basis for treatment comparisons [28].
Although assessment of achievement of multiple
therapeutic goals is very useful for individualized case
management, our results demonstrate the limitations
and pitfalls of such applications to studies of patient
populations that are not matched in terms of pre-
treatment characteristics and potentially confounding
concurrent or emerging medical events. Although the
percentages of our patients completely at therapeutic
goal after a median 12 years of GD1 treatment was lessTable 9 GD1 Genotypes in different world populations
Country or Region N370S/N370S (%)
Spain and Portugal (N = 370) 16.8
France* (N = 203) 19.2
Netherlands (N = 40 unrelated) 2.5
Italy (N = 106 unrelated) 12.3
UK and Ireland (N = 30) 30.3
Turkey (N = 32) 31.2
Latin America (N = 431) 11.7
World ICGG Registry 1998 (N = 680) 24.0
Jewish: USA and Israel (N = 545 unrelated)§ 45.0
AZ CT NJ NY, USA (N = 403) 53.6
South Florida, USA (N = 84 unrelated) 61.9
*Restricted to GD1 patients with at least one N370S allele.
§From Boot RG et al. Human Mutation. 10:348:1997.than that reported by ICCG after 4 years of treatment,
the clinical circumstances suggested that many “failures”
were probably not attributable to “breakthrough” mani-
festations of GD1. In fact, with the longer duration of
treatment, as predicted by the 10 year imiglucerase
experience [27], improvement in thrombocytopenia and
regression of hepatosplenomegaly exceeded that ob-
served in the ICGG study. Recurrent anemia was associ-
ated with onset of concurrent illnesses including renal
insufficiency, GI bleeding, or hematologic malignancy and
risk of death was clearly associated with aging and cumu-
lative co-morbidities. Persistent bone pain, the greatest
cause for failure to achieve all therapeutic goals, is difficult
to interpret objectively. Although chronic pre-treatment
bone pain was often persistent, we found that there was
little correlation with the presence of objective evidence of
bone damage such as infarction, osteonecrosis or prior
fractures, with severity of bone marrow infiltration and
osteopenia, or with overall DS3 severity score. As patients
age, it becomes more difficult to distinguish between
Gaucher bone pain and that attributable to other muscu-
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haviors not necessarily related to severity of GD1 based
on objective measurements. In a scientific study, can an
investigator legitimately dismiss positive patient pain re-
ports of uncertain relevance, without introducing the pos-
sibility of bias? If not, are the resultant aggregate “report
cards” an accurate measure of outcome? The contextual
relevance of bone pain reports would be enhanced by ac-
companying assessments of duration and constancy of
pain, effects on activities of daily living including school
and work performance and fluctuations in the use of adju-
vant analgesic medications.
The clinical outcomes research field is increasingly
emphasizing the centrality of patient-reported input and
value-based medicine (the ability of an intervention to
produce a clinical benefit in actual practice) as a neces-
sary accompaniment to classical efficacy and safety stud-
ies with physician-conceived endpoints (evidence-based
medicine) [29,30]. Rare, chronic, phenotypically hetero-
geneous diseases such as GD1 for which treatment,
when indicated, is generally lifelong and very expensive,
are prime targets for value-based research studies that
are applicable not only to individual patient care choices
but also to justification of societal health care priorities.
Our experiences with the medical complexity of a “sim-
ple Mendelian hereditary disease” population [31], with
the confounding effects of age-acquired co-morbidities
on even precisely defined and measured end points such
as hemoglobin concentration and with the difficulties in
contextual interpretation of patient-reported symptoms
such as bone pain highlight the need for expert guidance
when implementing patient-centered outcomes research
[32]. Although such studies strive to maximize patient
creativity and freedom of expression, they nonetheless
require careful design and annotation of patient charac-
teristics, clear objectives, defined nomenclature, and for-
mulation of focused and unambiguous questions that
are meaningful and important to the participants but
whose answers will be internally consistent and amen-
able to rigorous analysis.
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